Drug Trial Radar · NCT03551964
Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction
Last checked: Nov 20, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
605
Actual
Start
Aug 1, 2018
Primary completion
Feb 19, 2024
Study completion Apr 1, 2025
Sponsor
- Lead sponsor
- Faculty Hospital Kralovske VinohradyGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Charles University, Czech Republic; Masaryk University; Ministry of Health, Czech Republic; National Institute for Metabolic and Cardiovascular Disease Research; Institute of Hematology and Blood Transfusion, Czech Republic; BioVendor LM
- First posted
- Jun 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, international, randomized, placebo-controlled, double-blind trial comparing intravenous cangrelor and crushed oral ticagrelor in patients with acute myocardial infarction complicated by initial cardiogenic shock (CS-AMI) and treated with primary angioplasty (PCI). The Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction (DAPT-SHOCK-AMI) trial tests the hypothesis that intravenous cangrelor is (a) more effective in terms of its rate of onset and the proportion of patients achieving effective periprocedural inhibition of ADP-induced platelet aggregation and (b) at least as effective as the recommended treatment of oral (crushed) ticagrelor in reducing major cardiovascular events in patients with initial CS-AMI indicated for primary PCI strategy.
Conditions
- Acute Myocardial Infarction
- Cardiogenic Shock
Interventions
CangrelorDrug
Cangrelor: IV bolus 30 µg/kg (application \< 1 minute) followed immediately by continuous infusion at 4 µg/kg. Tables to calculate bolus dose in ml and infusion (in ml per hour) rate for each body weight group will be prepared in advance and will be included in the study medication kit to accelerate treatment start. * Cangrelor treatment will be discontinued after circulatory stabilization (but no earlier than 2 hours after infusion initiation) i.e. after systolic Blood Pressure (sBP) is maintained at the level \> 100 mmHg for one hour after the end of IABK and/or vasoactive treatment is discontinued, but no later than 4 hours after PCI, * 30 minutes before the end of Cangrelor infusion, administration of Ticagrelor 180 mg (crushed tablets) and then dose 90 mg every 12 hours.
TicagrelorDrug
Ticagrelor: 180 mg loading dose - crushed tablets, 2 x 90 mg maintenance dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Laboratory endpointTime frame: At the end of primary percutaneous coronary intervention; Within 24 hours from randomization
- Primary Clinical EndpointTime frame: Within 30 days after randomization
Locations
29 sites in 5 countries. Site status is shown where the registry gives one.
St. Anne's University Hospital Brno
Brno, Czechia
Department of Cardiology, University Hospital Brno-Bohunice
Brno, Czechia
Cardiology Department, Regional Hospital
České Budějovice, Czechia
University Hospital Hradec Králové
Hradec Králové, Czechia
Cardiology department, Regional hospital
Jihlava, Czechia
Cardiocenter, Regional Hospital
Karlovy Vary, Czechia
Krajská nemocnice Liberec
Liberec, Czechia
University Hospital Olomouc
Olomouc, Czechia
University Hospital Ostrava
Ostrava, Czechia
Department of Cardiology, Regional Hospital,
Pardubice, Czechia
University Hospital Pilsen
Pilsen, Czechia
General University Hospital in Prague
Prague, Czechia
Institute of Clinical and Experimental Medicine
Prague, Czechia
Na Homolce Hospital
Prague, Czechia
Cardiocenter, Hospital Podlesi
Třinec, Czechia
Masaryk Hospital
Ústí nad Labem, Czechia
Regional Hospital T. Bati
Zlín, Czechia
University Hospital Kralovske Vinohrady
Prague, Please Select, Czechia
Département de Cardiologie, Hôpital Bichat Assistance Publique Hôpitaux de Paris
Paris, France
Pitié-Salpêtrière Hospital (AP-HP)
Paris, France
Heart Center Freiburg University
Freiburg im Breisgau, Germany
University Medical Centre
Mannheim, Germany
University Hospital Tübingen
Tübingen, Germany
Collegium Medicum University Hospital No. 1
Bydgoszcz, Poland
Jagiellonianan University, University Hospital Krakow
Krakow, Poland
Medical University of Warsaw
Warsaw, Poland
Middle-Slovak Institute of Cardiovascular Diseases
Banská Bystrica, Slovakia
Center of Interventional Neuroradiology and Endovascular Treatment
Bratislava, Slovakia
Cardiocentre
Nitra, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.